Disease control intervals in high-risk neuroblastoma

Victor M. Santana, Wayne L. Furman, Lisa McGregor, Catherine A. Billups

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

BACKGROUND. Current salvage therapy for recurrent high-risk neuroblastoma is rarely curative. Assessment of the effectiveness of new, primarily cytostatic agents requires the redefinition of study endpoints to reflect disease stabilization rather than tumor response or regression. The intervals of disease control in the patients in the current study with recurrent neuroblastoma were characterized to provide comparison criteria for exploratory studies of new agents. METHODS. Disease control intervals, disease-free survival, postrecurrence survival, and median time to treatment failure were estimated in 90 patients with high-risk neuroblastoma treated between January 1991 and June 2002 on 3 St. Jude neuroblastoma protocols. RESULTS. The estimated median time to disease recurrence was 18.3 months (95% confidence interval [95% CI], 15.9-22.4 months) for the first recurrence, 8.7 months (95% CI, 5.0-12.2 months) for the second recurrence, and 3.8 months (95% CI, 2.5-5.4 months) for the third recurrence. The 5-year estimate of survival after the first disease recurrence was 11% ± 4%. Patients with longer initial disease control had a postrecurrence survival advantage:the 5-year estimated postrecurrence survival was 15.3% ± 6.3% for patients with initial disease control ≥16 months and 8.1% ± 5.5% for others (P = .006). The median disease control interval was approximately halved after each disease recurrence. CONCLUSIONS. The previous disease control interval should be considered in stratification schemes for future phase 2 testing of new agents for the treatment of neuroblastoma. For the optimal evaluation of new treatment strategies that incorporate cytostatic agents, study design and selection of endpoints must take into account the current patterns of recurrence or progression of neuroblastoma.

Original languageEnglish (US)
Pages (from-to)2796-2801
Number of pages6
JournalCancer
Volume112
Issue number12
DOIs
StatePublished - Jun 15 2008

Fingerprint

Neuroblastoma
Recurrence
Survival
Cytostatic Agents
Confidence Intervals
Salvage Therapy
Treatment Failure
Disease-Free Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Santana, V. M., Furman, W. L., McGregor, L., & Billups, C. A. (2008). Disease control intervals in high-risk neuroblastoma. Cancer, 112(12), 2796-2801. https://doi.org/10.1002/cncr.23507
Santana, Victor M. ; Furman, Wayne L. ; McGregor, Lisa ; Billups, Catherine A. / Disease control intervals in high-risk neuroblastoma. In: Cancer. 2008 ; Vol. 112, No. 12. pp. 2796-2801.
@article{fe8a256269da434aa241f670fe0e0e29,
title = "Disease control intervals in high-risk neuroblastoma",
abstract = "BACKGROUND. Current salvage therapy for recurrent high-risk neuroblastoma is rarely curative. Assessment of the effectiveness of new, primarily cytostatic agents requires the redefinition of study endpoints to reflect disease stabilization rather than tumor response or regression. The intervals of disease control in the patients in the current study with recurrent neuroblastoma were characterized to provide comparison criteria for exploratory studies of new agents. METHODS. Disease control intervals, disease-free survival, postrecurrence survival, and median time to treatment failure were estimated in 90 patients with high-risk neuroblastoma treated between January 1991 and June 2002 on 3 St. Jude neuroblastoma protocols. RESULTS. The estimated median time to disease recurrence was 18.3 months (95{\%} confidence interval [95{\%} CI], 15.9-22.4 months) for the first recurrence, 8.7 months (95{\%} CI, 5.0-12.2 months) for the second recurrence, and 3.8 months (95{\%} CI, 2.5-5.4 months) for the third recurrence. The 5-year estimate of survival after the first disease recurrence was 11{\%} ± 4{\%}. Patients with longer initial disease control had a postrecurrence survival advantage:the 5-year estimated postrecurrence survival was 15.3{\%} ± 6.3{\%} for patients with initial disease control ≥16 months and 8.1{\%} ± 5.5{\%} for others (P = .006). The median disease control interval was approximately halved after each disease recurrence. CONCLUSIONS. The previous disease control interval should be considered in stratification schemes for future phase 2 testing of new agents for the treatment of neuroblastoma. For the optimal evaluation of new treatment strategies that incorporate cytostatic agents, study design and selection of endpoints must take into account the current patterns of recurrence or progression of neuroblastoma.",
author = "Santana, {Victor M.} and Furman, {Wayne L.} and Lisa McGregor and Billups, {Catherine A.}",
year = "2008",
month = "6",
day = "15",
doi = "10.1002/cncr.23507",
language = "English (US)",
volume = "112",
pages = "2796--2801",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

Santana, VM, Furman, WL, McGregor, L & Billups, CA 2008, 'Disease control intervals in high-risk neuroblastoma', Cancer, vol. 112, no. 12, pp. 2796-2801. https://doi.org/10.1002/cncr.23507

Disease control intervals in high-risk neuroblastoma. / Santana, Victor M.; Furman, Wayne L.; McGregor, Lisa; Billups, Catherine A.

In: Cancer, Vol. 112, No. 12, 15.06.2008, p. 2796-2801.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Disease control intervals in high-risk neuroblastoma

AU - Santana, Victor M.

AU - Furman, Wayne L.

AU - McGregor, Lisa

AU - Billups, Catherine A.

PY - 2008/6/15

Y1 - 2008/6/15

N2 - BACKGROUND. Current salvage therapy for recurrent high-risk neuroblastoma is rarely curative. Assessment of the effectiveness of new, primarily cytostatic agents requires the redefinition of study endpoints to reflect disease stabilization rather than tumor response or regression. The intervals of disease control in the patients in the current study with recurrent neuroblastoma were characterized to provide comparison criteria for exploratory studies of new agents. METHODS. Disease control intervals, disease-free survival, postrecurrence survival, and median time to treatment failure were estimated in 90 patients with high-risk neuroblastoma treated between January 1991 and June 2002 on 3 St. Jude neuroblastoma protocols. RESULTS. The estimated median time to disease recurrence was 18.3 months (95% confidence interval [95% CI], 15.9-22.4 months) for the first recurrence, 8.7 months (95% CI, 5.0-12.2 months) for the second recurrence, and 3.8 months (95% CI, 2.5-5.4 months) for the third recurrence. The 5-year estimate of survival after the first disease recurrence was 11% ± 4%. Patients with longer initial disease control had a postrecurrence survival advantage:the 5-year estimated postrecurrence survival was 15.3% ± 6.3% for patients with initial disease control ≥16 months and 8.1% ± 5.5% for others (P = .006). The median disease control interval was approximately halved after each disease recurrence. CONCLUSIONS. The previous disease control interval should be considered in stratification schemes for future phase 2 testing of new agents for the treatment of neuroblastoma. For the optimal evaluation of new treatment strategies that incorporate cytostatic agents, study design and selection of endpoints must take into account the current patterns of recurrence or progression of neuroblastoma.

AB - BACKGROUND. Current salvage therapy for recurrent high-risk neuroblastoma is rarely curative. Assessment of the effectiveness of new, primarily cytostatic agents requires the redefinition of study endpoints to reflect disease stabilization rather than tumor response or regression. The intervals of disease control in the patients in the current study with recurrent neuroblastoma were characterized to provide comparison criteria for exploratory studies of new agents. METHODS. Disease control intervals, disease-free survival, postrecurrence survival, and median time to treatment failure were estimated in 90 patients with high-risk neuroblastoma treated between January 1991 and June 2002 on 3 St. Jude neuroblastoma protocols. RESULTS. The estimated median time to disease recurrence was 18.3 months (95% confidence interval [95% CI], 15.9-22.4 months) for the first recurrence, 8.7 months (95% CI, 5.0-12.2 months) for the second recurrence, and 3.8 months (95% CI, 2.5-5.4 months) for the third recurrence. The 5-year estimate of survival after the first disease recurrence was 11% ± 4%. Patients with longer initial disease control had a postrecurrence survival advantage:the 5-year estimated postrecurrence survival was 15.3% ± 6.3% for patients with initial disease control ≥16 months and 8.1% ± 5.5% for others (P = .006). The median disease control interval was approximately halved after each disease recurrence. CONCLUSIONS. The previous disease control interval should be considered in stratification schemes for future phase 2 testing of new agents for the treatment of neuroblastoma. For the optimal evaluation of new treatment strategies that incorporate cytostatic agents, study design and selection of endpoints must take into account the current patterns of recurrence or progression of neuroblastoma.

UR - http://www.scopus.com/inward/record.url?scp=46049086610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46049086610&partnerID=8YFLogxK

U2 - 10.1002/cncr.23507

DO - 10.1002/cncr.23507

M3 - Article

C2 - 18429000

AN - SCOPUS:46049086610

VL - 112

SP - 2796

EP - 2801

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -

Santana VM, Furman WL, McGregor L, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer. 2008 Jun 15;112(12):2796-2801. https://doi.org/10.1002/cncr.23507